LOUISVILLE, Ky. -- Large tumor size and high disease grade were associated with an increased risk of early cancer-related ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

There remains a high medical need for these head and neck cancer patients, as approximately 30% of them are expected to experience a relapse within 24 months after standard surgery and adjuvant ...

However, patients with MSI did not see improvements in DFS or OS with the addition of adjuvant or perioperative chemotherapy. These findings were published in the Journal of Gastrointestinal Surgery.

TUESDAY, Nov. 12, 2024 (HealthDay News) — Topical human platelet extract (HPE) performs as well as topical vitamin C for skin ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Welcome to Natera’s 2024 Third Quarter Financial Results ...